Loading organizations...
Loading organizations...

Asterix Foods: Biotech company developing scalable plant cell culture systems for animal-free bioactive protein production for the food industry.
Asterix Foods is a Tel Aviv, Israel-based biotechnology company that develops plant cell culture systems to produce high-value bioactive proteins, such as dairy and egg proteins, as an alternative to traditional precision fermentation. The company utilizes suspension cultures within modular bioreactors to manufacture bioactive glycoproteins like lactoferrin and ovomucoid for nutrition and health applications. By licensing its patent-pending technology, cell lines, and bioreactors to ingredient and dairy manufacturers, the firm aims to reduce facility costs by more than 95 percent. Operating a pilot facility with a team of eight doctoral-level researchers, the enterprise recently emerged from stealth mode after securing $4.2 million in seed funding. This financing round was supported by notable investors including CPT Capital, ReGen Ventures, SOSV, Grok Ventures, and the Israeli Innovation Authority. Asterix Foods was founded in 2022 by Dan Even.
Asterix Foods has raised $4.0M across 1 funding round.
Asterix Foods has raised $4.0M in total across 1 funding round.
Asterix Foods is an Israeli food-tech startup developing bioactive, animal-free proteins using plant cell suspension cultures in Massively Parallel Modular Bioreactors (MPMB). It serves food, nutrition, and health industries by producing functional proteins—like dairy and egg alternatives—as drop-in replacements for existing products, solving high costs, long timelines, and scalability issues of precision fermentation at over 95% lower facility costs, room-temperature operation, and continuous production.[1][2][3]
The company emerged from stealth in October 2025 with $4.2M in seed funding, operating a pilot in Tel Aviv with a team of eight scientists and engineers. Its platform enables year-round output, modular scaling, and global deployment near manufacturing hubs, targeting glycoproteins that precision fermentation struggles with due to glycosylation challenges.[1][2][5]
Founded in 2022 by Dan Even, CEO with a PhD in Plant Molecular Biology and Genetic Engineering from the Weizmann Institute of Science, Asterix Foods addressed limitations in microbial precision fermentation for complex bioactive proteins.[1][5] The idea stemmed from plant cells' natural ability to achieve precise glycosylations—essential for protein folding and functionality in food—while growing at ambient temperatures with cheaper media, unlocking a "second wave" of animal-free proteins after pioneers like Impossible Foods and Perfect Day.[2][5]
Early traction came via IndieBio accelerator, raising initial funding to $1.5M+ before the $4.2M seed round. Pivotal was building a pilot facility in a Tel Aviv office block, proving flexible, low-CAPEX production without cleanrooms or resource-heavy setups.[1][5]
Asterix stands out in alt-protein production through these key advantages:
Asterix rides the animal-free protein wave, targeting the "second wave" of complex glycoproteins post-heme proteins, amid rising demand for sustainable, functional alt-dairy/egg in a $1T+ food market strained by animal agriculture's emissions and costs.[2][3][5] Timing aligns with precision fermentation's maturation—e.g., Perfect Day, Impossible—yet its pitfalls (high CapEx, downtime, glycosylation limits) create Asterix's niche.[1][2]
Market forces favor it: climate pressures, non-arable land availability, and food giants seeking drop-in solutions without reformulation. By enabling cheap, weather-independent production anywhere, Asterix influences the ecosystem toward decentralized, low-carbon biomanufacturing, potentially accelerating alt-protein adoption and pressuring traditional ag.[1][3]
Asterix is poised to license its platform widely in 2026+, starting with pilot partners scaling to commercial runs, as modular tech de-risks adoption for dairy/ingredient firms.[2] Trends like glycoprotein demand, energy-efficient biotech, and on-site manufacturing will propel growth, evolving its role from innovator to enabler of animal-free food chains.
This positions Asterix to redefine scalable proteins, delivering bioactive functionality at precision fermentation's fraction of the cost—unlocking sustainable food without compromise.[1][3]
Asterix Foods has raised $4.0M in total across 1 funding round.
Asterix Foods's investors include CPT Capital, Amazon Climate Pledge Fund, SOSV, Grok Ventures, Israeli Innovation Authority, ReGen Ventures.
Asterix Foods has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $4.0M Seed | CPT Capital | Amazon Climate Pledge Fund, SOSV, Grok Ventures, Israeli Innovation Authority, ReGen Ventures |